Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:46:55 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:SRPT - SAREPTA THERAPEUTICS INC - https://www.sareptatherapeutics.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SRPT - Q2.017.90·18.650.118.50+1.478.63,171.556,56325,55517.59  18.635  17.512114.4122  10.41519:56:57Feb 0415 min RT 2¢

Recent Trades - Last 10 of 25555
Time ETExPriceChangeVolume
19:56:57Q18.521.4930
19:56:23Q18.521.49500
19:54:52Q18.52351.49351
19:53:51Q18.661.63100
19:53:51Q18.661.63400
19:53:32Q18.661.63300
19:53:32Q18.661.63700
19:41:10Q18.661.635
19:38:41Q18.661.635
19:28:51Q18.65671.62671,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 08:30U:SRPTNews ReleaseSarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
2026-01-26 08:00U:SRPTNews ReleaseSarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
2026-01-23 16:05U:SRPTNews ReleaseSarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
2026-01-12 11:58U:SRPTNews ReleaseSarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
2026-01-07 08:30U:SRPTNews ReleaseSarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease
2026-01-05 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-31 17:20U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-11 07:00U:SRPTNews ReleaseSarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
2025-11-25 08:57U:SRPTNews ReleaseSarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
2025-11-24 07:30U:SRPTNews ReleaseSarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
2025-11-14 14:54U:SRPTNews ReleaseSarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information
2025-11-03 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
2025-10-27 16:05U:SRPTNews ReleaseSarepta Therapeutics to Announce Third Quarter 2025 Financial Results
2025-10-21 06:46U:SRPTNews ReleaseTradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
2025-10-03 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
2025-09-30 18:00U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-05 09:00U:SRPTNews ReleaseSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
2025-08-26 18:15U:SRPTNews ReleaseElanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
2025-08-21 07:00U:SRPTNews ReleaseSarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027
2025-08-13 16:12U:SRPTNews ReleaseSarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment